HONG KONG – Shortly after Australia’s recent provisional approval for the mRNA-based COVID-19 vaccine Comirnaty (tozinameran), originally developed by Pfizer Inc. and Biontech SE, Hong Kong has approved it, too, for emergency use ahead of rivals developed in mainland China. It is the first vaccine to be approved in the Chinese territory, made possible through a collaboration between Biontech and Shanghai Fosun Pharmaceutical Group Co. Ltd. Read More

PERTH, Australia – Sydney-based Cyclopharm Ltd. raised AU$30 million (US$23.19 million) in a private placement that will enable the company to launch its Technegas combination product in the U.S. Read More

PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval to Pfizer Australia Pty Ltd. for its COVID-19 vaccine, branded Comirnaty, making it the first COVID-19 vaccine to receive approval in Australia. Read More

PERTH, Australia – Sydney-based Immutep Ltd. announced that Glaxosmithkline plc is discontinuing a phase II ulcerative colitis trial of its anti-lymphocyte activation gene-3 cell-depleting monoclonal antibody, derived from Immutep’s IMP-731 antibody that GSK licensed in 2010. Read More

When it comes to leveling the playing field for foreign-based biopharma and medical device companies, China has made a lot of promises, but delivering on those promises is what matters. Read More

The record pace of biopharmas filing for IPOs in the U.S. continues as five more companies filed SEC paperwork, looking for gross proceeds totaling $356 million. In 2020, 106 new offerings were completed and raised $22.5 billion, more than double 2018's record of $10.7 billion. Read More

HONG KONG – Irvine, Calif.-based Trigr Therapeutics Inc. has signed an exclusive licensing deal with Shanghai-based Elpiscience Biopharmaceuticals Co. Ltd., known as Kewang in China. The two companies will develop and commercialize TR-009 in mainland China, Hong Kong, Macau and Taiwan. Read More

New hires and promotions in the biopharma industry in Asia-Pacific, including: Connect. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Adagene, Biophytis, Covicept, Fulcrum, Inovio, Pneumagen. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Abcellera, Algernon, Aribio, Aslan, Biophytis, Bio-Thera Solutions, Brickell, Cardiol, Debiopharm, Dynavax, Eli Lilly, Grifols, Immutep, Jemincare, Kaken, Medigen Vaccine, Moderna, Senhwa, Sinomab, Synairgen, Zydus Cadila. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: AB Science, Achilles Vaccines, Advita Lifescience, Amarin, Betterlife, Beximco, Biontech, Boehringer Ingelheim, Conserv, Continuus, Cure Genetics, Daiichi Sankyo, Edding, Elasmogen, Elpiscience, Emergent Biosolutions, Equilab International, Etana Biotechnologies Hong Kong, Everest Medicines, Evozyne, Faron, GB Sciences, Genevant Sciences, Gritstone Oncology, Hanmi, Humanigen, Immunitybio, Immunotech, Innovent Biologics, Intravacc, Invixa, Johnson & Johnson, LG Chem, Microba Life Sciences, Neurophth, Novavax, Nyrada, Oxford, Pfizer, Pharmadrug, Propanc, Relief, Sairiyo, Samsung Bioepis, Sanofi, Sorrento, Spero, Syntekabio, Takeda, T-Cure, Tennor, Trigr, VBI Vaccines, Vigeneron, Wuxi Biologics, Xbiotech. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Adamis, Astrazeneca, Beigene, Biocelect, Biocryst, Clinigen, Daiichi Sankyo, Dr. Reddy’s, Edigene, Eubiologics, Eusa, Eutilex, GC, Gracell, Helsinn, Immunitybio, Medolife Rx, Novavax, Ono, Pfizer, Russian Direct Investment Fund, Shanghai Junshi, Tessa, Tracon, Turn, Waymade Australia. Read More

The latest global regulatory news, changes and updates affecting biopharma in Asia, including: Therapeutic Goods Administration. Read More